Grufity logoGrufity logo

bluebird bio Inc Stock Research

BLUE

6.28USD+0.05(+0.80%)Market Closed

Market Summary

USD6.28+0.05
Market Closed
0.80%

BLUE Stock Price

BLUE RSI Chart

BLUE Valuation

Market Cap

520.5M

Price/Earnings (Trailing)

-1.15

Price/Sales (Trailing)

107.39

EV/EBITDA

-1.07

Price/Free Cashflow

-1.17

BLUE Price/Sales (Trailing)

BLUE Profitability

EBT Margin

-7079.01%

Return on Equity

-285.7%

Return on Assets

-87.26%

Free Cashflow Yield

-85.71%

BLUE Fundamentals

BLUE Revenue

Revenue Y/Y

962.24%

Revenue Q/Q

-21.9%

BLUE Earnings

Earnings (TTM)

-453.9M

Earnings Y/Y

64.71%

Earnings Q/Q

23.59%

Price Action

52 Week Range

2.878.58
(Low)(High)

Last 7 days

1.3%

Last 30 days

-4.7%

Last 90 days

0.6%

Trailing 12 Months

-14.0%

BLUE Financial Health

Current Ratio

1.27

BLUE Investor Care

Shares Dilution (1Y)

20.78%

Diluted EPS (TTM)

-6.1

Peers (Alternatives to bluebird bio)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
135.3B
26.3B
-2.97% 16.81%
19.8
5.14
2.18% 21.86%
105.0B
27.1B
-0.99% 30.15%
31.49
3.87
-1.26% -54.91%
73.3B
21.4B
7.28% 27.41%
6.23
3.43
80.80% 66.62%
41.9B
10.4B
5.85% 32.49%
14.62
4.04
-6.64% 85.32%
10.4B
1.4B
-8.79% 49.41%
178.74
7.49
29.86% -86.92%
MID-CAP
3.9B
-
18.31% 0.06%
-12.88
32.03
-41.50% -1123.42%
3.2B
-
23.33% -24.11%
-10.12
59.51
215916.67% 21.41%
SMALL-CAP
1.7B
432.8M
17.41% -21.00%
20.97
3.87
1042.97% 128.67%
1.4B
-
35.16% 1.79%
-2.74
20.84
745.14% 12.80%
1.3B
3.1M
-3.43% 39.57%
-8.78
417.83
7.05% -46.74%
886.0M
1.8B
24.61% -84.52%
-0.67
0.48
53.41% -22.97%
574.9M
69.0M
-39.96% -83.45%
-1.96
8.33
26.22% -49.52%
565.8M
112.1M
28.78% -35.14%
-3.18
5.05
3.26% 1.99%
142.4M
-
42.67% -74.19%
-1.36
418.24
-71.03% -64.56%
6.7M
-
67.66% -93.12%
-0.11
3.21
0.51% -141.69%

Financials for bluebird bio

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-100.0%null6,089,0004,713,00053,917,200103,121,400
  S&GA Expenses-5.2%159,408,000168,235,000186,525,000209,969,000190,810,000
  R&D Expenses-7.0%274,250,000294,780,000315,584,000319,946,000109,614,000
Costs and Expenses-13.5%453,335,000523,951,000569,876,000594,573,000596,687,000
EBITDA14.5%-424,982,000.00-496,821,000.00-463,487,000.00-542,731,000.00-
EBITDA Margin14.5%-69.80-81.59-8.71-5.41-
Earnings Before Taxes15.1%-431,041,000.00-507,475,000.00-563,094,000.00-562,380,000.00-572,124,000.00
EBT Margin15.1%-70.79-83.34-9.00-5.61-
Interest Expenses-0----
Net Income23.6%-453,862,000.00-594,158,000.00-735,722,000.00-819,378,000.00-864,200,000.00
Net Income Margin23.6%-74.54-97.58-13.83-8.17-
Free Cahsflow14.0%-446,084,000.00-518,453,000.00-565,330,000.00-650,103,000.00-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-9.3%5205744915941,340
  Current Assets-4.2%160167255337832
    Cash Equivalents-18.4%6681106161402
  Inventory-100.0%-1---
  Net PPE-20.8%1215111046
  Goodwill0%666612
Liabilities-8.2%361393228220469
  Current Liabilities-14.9%127149143153267
Shareholder's Equity-11.8%159180263374871
  Retained Earnings-2.0%-4,020.00-3,942.21-3,842.08-3,719.92-3,560.00
  Additional Paid-In Capital1.3%4,1814,1264,1094,0964,441
Accumulated Depreciation4.8%2423212059
Shares Outstanding12.7%8374717169
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations13.8%-436.42-506.32-557.61-635.64-651.11
  Share Based Compensation-25.1%577698128135
Cashflow From Investing-33.4%208312311563650
Cashflow From Financing-32.8%-119.65-90.10-97.74-93.9581

Risks for BLUE

What is the probability of a big loss on BLUE?

98.1%


Probability that bluebird bio stock will be more than 20% underwater in next one year

93.1%


Probability that bluebird bio stock will be more than 30% underwater in next one year.

85.4%


Probability that bluebird bio stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BLUE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if bluebird bio was unfortunately bought at previous high price.

Drawdowns

Returns for BLUE

Cumulative Returns on BLUE

-23.6%


7-Year Cumulative Returns

-50.0%


5-Year Cumulative Returns

-57.9%


3-Year Cumulative Returns

What are the long-term rolling returns for BLUE?

FIve years rolling returns for bluebird bio.

Annualized Returns

Which funds bought or sold BLUE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-25
WHITTIER TRUST CO
unchanged
-
491
2,491
-%
2023-01-25
Lindbrook Capital, LLC
added
165.58
3,661
5,661
-%
2023-01-24
BAILLIE GIFFORD & CO
unchanged
-
1,000
6,000
-%
2023-01-23
Allspring Global Investments Holdings, LLC
reduced
-2.14
11,132
163,132
-%
2023-01-19
Quent Capital, LLC
unchanged
-
19,360
228,360
0.04%
2023-01-18
BOYD WATTERSON ASSET MANAGEMENT LLC/OH
new
-
858
858
-%
2023-01-18
Verition Fund Management LLC
new
-
466,000
466,000
-%
2023-01-12
Hennion & Walsh Asset Management, Inc.
added
11.07
126,000
714,000
0.04%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-0.36
66,000
193,000
-%
2022-11-21
FourThought Financial, LLC
unchanged
-
-
-
-%

1–10 of 40

Latest Funds Activity

Are funds buying BLUE calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BLUE
No. of Funds

bluebird bio News

Marketing Sentinel

bluebird bio Inc. (NASDAQ:BLUE) Is Now 53.93% Above Its 52 ....

Marketing Sentinel,
45 hours ago

InvestorsObserver

InvestorsObserver

InvestorsObserver

InvestorsObserver

Schedule 13G FIlings of bluebird bio

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 25, 2023
blackrock inc.
8.9%
7,367,181
SC 13G/A
Jan 12, 2023
millennium management llc
1.2%
973,085
SC 13G/A
Sep 09, 2022
wellington management group llp
0.32%
244,061
SC 13G/A
Aug 01, 2022
millennium management llc
5.4%
3,873,900
SC 13G
Jul 11, 2022
vanguard group inc
4.91%
3,506,909
SC 13G/A
Jul 11, 2022
state street corp
2.55%
1,825,101
SC 13G/A
Jun 03, 2022
tang capital partners lp
5.2%
3,721,056
SC 13G
Apr 11, 2022
state street corp
18.41%
13,151,891
SC 13G/A
Feb 09, 2022
vanguard group inc
10.32%
7,233,590
SC 13G/A
Feb 04, 2022
wellington management group llp
8.76%
6,140,000
SC 13G/A

BLUE Fair Value

Recent SEC filings of bluebird bio

View All Filings
Date Filed Form Type Document
Jan 25, 2023
SC 13G/A
Major Ownership Report
Jan 19, 2023
424B5
Prospectus Filed
Jan 19, 2023
8-K
Current Report
Jan 18, 2023
424B5
Prospectus Filed
Jan 13, 2023
4
Insider Trading
Jan 13, 2023
4
Insider Trading
Jan 13, 2023
4
Insider Trading
Jan 12, 2023
SC 13G/A
Major Ownership Report
Jan 09, 2023
3
Insider Trading
Jan 09, 2023
8-K
Current Report

Latest Insider Trading transactions for BLUE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-11
Colvin Richard A
sold
-4,347
7.8043
-557
chief medical officer
2023-01-11
Obenshain Andrew
sold
-24,802.1
7.8043
-3,178
president and ceo
2023-01-11
Leschly Nick
sold
-33,480.4
7.8043
-4,290
-
2022-12-01
Krawtschuk Christopher
acquired
-
-
50,000
chief financial officer
2022-11-04
Colvin Richard A
sold
-1,398.19
6.4137
-218
chief medical officer
2022-11-04
Obenshain Andrew
sold
-8,100.5
6.4137
-1,263
president and ceo
2022-11-01
Colvin Richard A
acquired
-
-
30,000
chief medical officer
2022-09-01
Klima Thomas J
acquired
-
-
11,000
see remarks
2022-08-19
Cole Jason
sold
-78,472.9
5.5286
-14,194
chief strategy & financial off
2022-08-04
Cole Jason
sold
-32,707.1
4.3914
-7,448
chief strategy & financial off

1–10 of 50

Andrew Obenshain
520
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

BLUE Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenues$ 71$ 1,019$ 3,534$ 2,056
Operating expenses:    
Research and development53,14973,679194,864240,561
Selling, general and administrative33,40242,229106,201156,763
Cost of product revenue019,38510,05635,176
Restructuring expenses(1,699)20,1754,94024,800
Total operating expenses84,852155,468316,061457,300
Loss from operations(84,781)(154,449)(312,527)(455,244)
Interest income, net383160663733
Other (expense) income, net7,8851,34213,06124,369
Loss before income taxes(76,513)(152,947)(298,803)(430,142)
Income tax (expense) benefit(7)113(7)(169)
Net loss from continuing operations(76,520)(152,834)(298,810)(430,311)
Net loss from discontinued operations0(63,982)0(234,015)
Net loss$ (76,520)$ (216,816)$ (298,810)$ (664,326)
Net loss per share from continuing operations - basic (in dollars per share)$ (0.94)$ (2.23)$ (3.91)$ (6.36)
Net loss per share from continuing operations - diluted (in dollars per share)(0.94)(2.23)(3.91)(6.36)
Net loss per share from discontinued operations - basic (in dollars per share)0(0.93)0(3.46)
Net loss per share from discontinued operations - diluted (in dollars per share)0(0.93)0(3.46)
Net loss per share - basic (in dollars per share)(0.94)(3.16)(3.91)(9.81)
Net loss per share - diluted (in dollars per share)$ (0.94)$ (3.16)$ (3.91)$ (9.81)
Weighted-average number of common shares used in computing net loss per share - basic (in shares)81,54368,62176,36167,701
Weighted-average number of common shares used in computing net loss per share - diluted (in shares)81,54368,62176,36167,701
Other comprehensive (loss) income:    
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent$ (214)$ (129)$ (1,719)$ (401)
Comprehensive loss(76,734)(216,945)(300,529)(664,727)
Product revenue    
Revenue:    
Revenue07682,7391,492
Other revenue    
Revenue:    
Revenue$ 71$ 251$ 795$ 564

BLUE Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 66,478$ 161,160
Marketable securities73,155138,343
Prepaid expenses8,27025,628
Receivables and other current assets12,53511,389
Total current assets160,438336,520
Marketable securities1,40797,114
Property, plant and equipment, net11,5359,706
Goodwill5,6465,646
Operating lease right-of-use assets288,68491,532
Restricted cash and other non-current assets52,38853,277
Total assets520,098593,795
Current liabilities:  
Accounts payable18,62225,883
Accrued expenses and other current liabilities64,314103,958
Operating lease liability, current portion43,79123,152
Total current liabilities126,727152,993
Operating lease liability, net of current portion234,42266,432
Other non-current liabilities9293
Total liabilities361,241219,518
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and outstanding at September 30, 2022 and December 31, 202100
Common stock, $0.01 par value, 125,000 shares authorized; 82,880 and 71,115 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively829711
Additional paid-in capital4,181,3934,096,402
Accumulated other comprehensive loss(4,630)(2,911)
Accumulated deficit(4,018,735)(3,719,925)
Total stockholders’ equity158,857374,277
Total liabilities and stockholders’ equity$ 520,098$ 593,795